Page 15 - Ace2 News Today

A team of scientists from the USA and Canada has recently characterized the antibodies developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in response to an mRNA-based coronavirus disease 2019 (COVID-19) vaccine.

A genetic variant of TMPRSS2 may confer protection against severe COVID-19 Among a large sample of coronavirus disease 2019 (COVID-19) patients, researchers found that a genetic variant – caused by an amino acid substitution from valine to methionine – is associated with a reduced chance of severe disease. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, can have a diverse range of effects on people. Some people develop no symptom...

Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.

A new study details the results from a single dose of the FINLAY FR 1A recombinant dimeric receptor-binding domain (RBD) base vaccine during a phase I clinical trial with 30 COVID-19 convalescents to test its capacity for boosting natural immunity.

Novel host-viral-microbiome interactions during COVID-19 may determine outcome The current pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been spreading rapidly for over a year. Though primarily a respiratory illness, its manifestations are often protean and may be life-threatening. A new preprint on the medRxiv* server discusses how the underlying disease mechanisms are regulated such that the local or mucosal i...

Researchers found a small molecule that inhibits different virus proteins and significantly reduces infection in cells. Combined with the antiviral remdesivir, its potency increases significantly, suggesting it may be a potential antiviral candidate for the treatment of COVID-19.

Early antibody response predicts COVID-19 outcome Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus behind the coronavirus disease 2019 (COVID-19) pandemic, has claimed over 2.54 million lives so far and affected more than 114 million people globally. In the U.S. alone, more than 516,000 deaths are attributed to the virus. Neutralizing antibodies targeting the SARS-CoV-2 spike protein are the most widely used candidates for developing vaccines and therapeutics....

Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the miniprotein, LCB1, against SARS-CoV-2-mediated lung disease in human ACE2-expressing transgenic mice.

Researchers at the New York State Department of Health in the United States have said concerning mutations within the B.1.526 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently become prevalent in New York State warrant further monitoring.

New research suggests Syrian golden hamsters could be a potentially useful preclinical model for testing vaccine immunity against the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.17 and B.1.351 variant.